AX09

**AX09** is an investigational antibody-based immunotherapy developed by Agilvax, Inc., targeting the cystine-glutamate antiporter **xCT** (encoded by **SLC7A11**), a transporter overexpressed in various cancers that supports tumor growth by importing cystine for glutathione synthesis and antioxidant defense. By inhibiting xCT function, AX09 disrupts tumor redox balance and metabolism, potentially enhancing immune-mediated tumor clearance; it has been explored in preclinical models including virus-like particle (VLP) formats like **Ax09-0m6** for inducing anti-xCT antibodies in breast cancer (e.g., 4T1 murine model) and metastatic breast cancer (**MBC**). An unrelated compound **AXS-09** (esbupropion + dextromethorphan) from Axsome Therapeutics targets CNS disorders but is distinct.